ESOC 2022 | ESOC 2022 highlights: tenecteplase non-inferiority and cancer risk in young stroke

Ana Catarina Fonseca, MD, PhD, University of Lisbon, Lisbon, Portugal, shares her highlights from the European Stroke Organisation Conference 2022, spotlighting clinical trials assessing the safety and efficacy of tenecteplase as practice changing developments. Several trials investigating thrombolytic treatment with tenecteplase at a dose of 0.25 mg/kg showed the agent to be at least as effective as alteplase, with no increase in hemorrhagic risk. The NOR-TEST 2 trial (NCT03854500) which assessed the dose of 0.4mg/kg found tenecteplase to give worse safety and functional outcomes compared to alteplase, indicating the lower dose should be used moving forward. Prof. Fonseca also discusses data shared showing an increased cancer risk in patients with young stroke with unknown etiology. This interview took place at European Stroke Organisation Conference 2022 in Lyon, France.